Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8041 to 8055 of 8905 results

  1. IQoro for hiatus hernia (MIB176)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  2. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

    Withdrawn advice

  3. LiverMultiScan for liver disease (MIB181)

    This advice has been updated and replaced by NICE healthtech guidance 655.

    Withdrawn advice

  4. SEM Scanner for pressure ulcer prevention (MIB182)

    This advice has been updated and replaced by NICE medical technologies guidance 51.

    Withdrawn advice

  5. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

    Withdrawn advice

  6. Danis stent for acute oesophageal variceal bleeds (MIB185)

    This advice has been updated and replaced by NICE healthtech guidance 574.

    Withdrawn advice

  7. Endo-SPONGE for colorectal anastomotic leakage (MIB188)

    This advice has been updated and replaced by NICE healthtech guidance 605.

    Withdrawn advice

  8. The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

    This advice has been updated and replaced by NICE healthtech guidance 566.

    Withdrawn advice

  9. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)

    This advice has been updated and replaced by NICE healthtech guidance 611.

    Withdrawn advice

  10. myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)

    This advice has been updated and replaced by NICE medical technologies guidance 68.

    Withdrawn advice

  11. Space from Depression for treating adults with depression (MIB215)

    This advice has been updated and replaced by NICE HealthTech guidance 675.

    Withdrawn advice

  12. FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)

    This advice has been updated and replaced by NICE healthtech guidance 682.

    Withdrawn advice

  13. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  14. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  15. Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)

    In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008

    Withdrawn guidance